Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Operating Income of $409.48 million for fiscal year 2025.
BIOMARIN PHARMACEUTICAL INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $409.48M | -15.4% |
| 2024 | $484.21M | +160.6% |
| 2023 | $185.77M | +15.4% |
| 2022 | $160.97M | +295.5% |
| 2021 | -$82.34M | -89.6% |
| 2020 | -$43.44M | +56.8% |
| 2019 | -$100.46M | +18.7% |
| 2018 | -$123.52M | -740.3% |
| 2017 | -$14.70M | +98.2% |
| 2016 | -$803.43M | -625.8% |
| 2015 | -$110.70M | -19.2% |
| 2014 | -$92.89M | +40.5% |
| 2013 | -$156.01M | -41.5% |
| 2012 | -$110.22M | -225.2% |
| 2011 | -$33.89M | -6329.8% |
| 2010 | $544.0K | -96.7% |
| 2009 | $16.43M | -58.7% |
| 2008 | $39.76M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$46.69M | -141.0% | -116.9% |
| June 30, 2025 | $276.89M | +129.9% | +23.7% |
| March 31, 2025 | $223.89M | +153.1% | +96.6% |
| September 30, 2024 | $113.89M | +273.1% | -5.4% |
| June 30, 2024 | $120.45M | +83.7% | +36.2% |
| March 31, 2024 | $88.46M | +41.8% | +189.8% |
| September 30, 2023 | $30.52M | +1362.9% | -53.4% |
| June 30, 2023 | $65.57M | +67.5% | +5.1% |
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -15.4% in Operating Income compared to the prior fiscal year.
- Over the 2008–2025 period, BIOMARIN PHARMACEUTICAL INC’s operating income has grown by 930.0% (from $39.76 million to $409.48 million).
- The most recent figure is from BIOMARIN PHARMACEUTICAL INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: